Signature Financial Management Inc. raised its holdings in Pfizer Inc. (NYSE:PFE) by 10.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 33,998 shares of the biopharmaceutical company’s stock after acquiring an additional 3,301 shares during the period. Signature Financial Management Inc.’s holdings in Pfizer were worth $1,111,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also modified their holdings of the company. Shine Investment Advisory Services Inc. purchased a new stake in shares of Pfizer during the 2nd quarter valued at $102,000. Mckinley Capital Management LLC Delaware purchased a new stake in shares of Pfizer during the 2nd quarter valued at $103,000. Herndon Capital Management LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at $120,000. Private Vista LLC grew its stake in shares of Pfizer by 2,277.3% during the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 190,933 shares during the period. Finally, Lipe & Dalton grew its stake in shares of Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the period. Institutional investors own 70.12% of the company’s stock.
A number of analysts recently weighed in on the stock. Sanford C. Bernstein set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, January 30th. Goldman Sachs Group set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. UBS Group set a $42.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Wednesday, January 31st. BMO Capital Markets set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Finally, Berenberg Bank set a $36.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $39.45.
In related news, EVP Rady A. Johnson sold 8,000 shares of the stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $37.07, for a total transaction of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares in the company, valued at $1,740,918.41. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $37.00, for a total transaction of $249,750.00. Following the sale, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Shares of Pfizer Inc. (NYSE:PFE) opened at $36.01 on Wednesday. The stock has a market cap of $214,650.00, a PE ratio of 10.23, a PEG ratio of 2.05 and a beta of 0.94. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer Inc. has a 12 month low of $31.67 and a 12 month high of $39.43.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.56 by $0.06. The business had revenue of $13.70 billion for the quarter, compared to analyst estimates of $13.67 billion. Pfizer had a net margin of 40.55% and a return on equity of 26.86%. The company’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.47 EPS. sell-side analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be paid a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.78%. The ex-dividend date is Thursday, February 1st. This is a positive change from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s dividend payout ratio is 38.64%.
Pfizer announced that its board has authorized a stock repurchase program on Monday, December 18th that allows the company to buyback $10.00 billion in outstanding shares. This buyback authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s leadership believes its shares are undervalued.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/21/signature-financial-management-inc-has-1-11-million-holdings-in-pfizer-inc-pfe.html.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.